Law360, New York (May 23, 2008, 12:00 AM ET) -- Rival biotechnology companies MedImmune Inc. and Genentech Inc. have reached a deal in the patent suit over MedImmune's blockbuster drug Synagis, signaling the end of a dispute that led to the U.S. Supreme Court's January 2007 decision that a patent licensee could challenge a patent's validity without breaching or terminating the licensing agreement.
A Genentech spokesperson on Friday confirmed that the two companies had reached a settlement and would be seeking dismissal of the litigation, which is in the U.S. District Court for the Central District...
MedImmune, Genentech Strike Deal In Synagis Case
To view the full article, take a free trial now.
